Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Pharm. 2019 Jun 14;16(7):2872–2883. doi: 10.1021/acs.molpharmaceut.8b01343

Figure 3. ALN-m inhibits the resorption activity of osteoclasts.

Figure 3.

(A) RAW264.7 cells were cultured on Osteo Surface plates and treated with RANKL (50 μg/mL) in the presence or absence of ALK or ALN-m as indicated. Polymer concentration is expressed based on ALN equivalents. The total area of the resorbed regions was quantified and normalized to the cells cultured in the presence of only RANKL (control). (B) RAW264.7 cells were first differentiated into osteoclasts on Osteo Surface plates in the presence of RANKL (50 μg/mL) for 4 days and then treated with ALK-m or ALN-m for next 3 days. Data are expressed as the mean ± SD (n = 3). **p < 0.01, NS - not significant.